VTT Technical Research Centre of Finland is a globally networked multitechnological contract research organization. VTT provides high-end technology solutions and innovation services. We enhance our customers’ competitiveness, thereby creating prerequisites for society’s sustainable development, employment, and wellbeing.

VTT has a strong tradition in research on ICT for wellness and healthcare. Our core competence includes: Biosignal and image processing; Personal Health Systems; eHealth/mHealth technologies; Bioinformatics and System analysis. Biosignal and medical image processing and interpretation is one of our key competencies. There we combine top-level technical expertise in the fields of signal processing, image processing, statistics, data-mining and pattern recognition with the understanding of healthcare-domain specific challenges to create solutions, simply for a better life.

ge_imagination_at_work.gifMedical Diagnostics (MDx) is a business unit within GE Healthcare Ltd. developing diagnostic imaging agents for CT, MR, SPECT and PET. These are used in medical scanning procedures to highlight organs, tissues and cells inside the human body, for the early detection, diagnosis and management of disease. Image analysis software, tailored to meet the specific needs of each imaging agent, is an increasingly important area. Responsibility for developing software to support GEHC’s imaging agents lies within the Image Processing & Software team within Medical Diagnostics R&D.

MDx R&D has offices in Amersham UK and in Princeton and the overall business unit is part of GE Healthcare Ltd UK. The team in Uppsala reports directly into MDx R&D UK and this is the reason why the legal entity is GEHC UK. It should also be noted that MDx R&D UK are studying the use of PET agents in TBI and although the PET data analysis will be done in Uppsala, the work will be done in close collaboration with the team in the UK.


Consistently rated amongst the world's best universities, Imperial College London is a science-based institution with a reputation for excellence in teaching and research. The Department of Computing at Imperial is one of the largest computing departments in the UK and is a world leader in academic research in computer science. There are over sixty academic staff which are actively involved in research.

Within the Department of Computing, the Biomedical Image Analysis research group is developing novel, computational techniques for the analysis of biomedical images. It focuses on both translational and cutting edge research in methodology driven areas of biomedical image analysis, such as registration, segmentation and shape modelling, addressing real-world problems in healthcare. Current work includes applications in machine learning, computer aided diagnosis, computer assisted therapy and interventions as well as clinical applications of medical image computing in neurology and oncology. The group has over 30 research staff and students, and has attracted significant funding from national and international research councils, industry and charities.

logo-neuro-uef-webosoite.jpgThe Department of Neurology at the University of Eastern Finland is a research center with experience in basic and clinical neurosciences. Researchers and staff are totalling 60. Since 1990, our PhD students have produced 94 doctoral dissertations. Annually, we produce 50-60 publications in international scientific journals.

Our research groups focus on basic mechanisms, prevention, drug and clinical research of degenerative brain diseases, particularly Alzheimer's disease. Most of our population-based surveys and drug trials are run at the Brain Research Unit. One focus is neuroimaging and developing new options for early diagnosis of Alzheimer's disease. There are also facilities for genetics and biomarker analysis for searching new risk genes using single nucleotide polymorphism analysis and functional studies.

rh2.jpgregionhvidescenterlogo.pngThe Memory Disorders Research Group (MDRG) at Rigshospitalet in Copenhagen, Denmark was established in 1995 as an outpatient memory clinic based in neurology with a multidisciplinary staff and research programs. Approximately 1500 patients MCI, AD, or other dementias are seen on a regular basis and 700 new patients are referred every year.

A member of the European Alzheimer’s Disease Consortium (EADC), the MDRG has a clinical research database, and a biobank is under development. The MDRG runs research programs in clinical dementia research and cognitive neurology (epidemiology, clinical genetics, structural and functional brain imaging, biomarkers, neuropsychology, and intervention studies). The core areas of expertise comprise longitudinal clinical assessments, development and validation of diagnostic markers, clinical development of potential pharmaceutical treatments including trial design, clinical genetics and molecular biology of familial disorders, clinical epidemiology, and health services in dementia. The MDRG collaborates with several in-house partners at Rigshospitalet, as well as with external and international partners.

logo_vumc_alzheimercentrum_eng_small.pngThe VUmc Alzheimer Center was founded in 2000 and is led by prof Philip Scheltens. Dr Wiesje van der Flier is member of the management team as head of research. The VUmc Alzheimer Center is dedicated to patient care and research of Alzheimer's disease and other types of dementia, with a special focus on dementia with early onset.

Over 500 new patients visit the VUmc Alzheimer Center every year. The Vumc Alzheimer Center implements a unique approach by diagnosing patients within one week. All necessary tests are performed in one day and patients are diagnosed by a multidisciplinary team during the weekly consensus meeting. Staff consists of five neurologists, five senior researchers, >20 PhD students, two specialized nurses and three neuropsychologists.

Scientific research is high on the agenda of the VUmc Alzheimer Center, resulting in a scientific output of over 50 international publications every year and position in the top 5 of the world.

Research has focused on early diagnosis, treatment and ultimately prevention. The influence of vascular factors and their contribution to cognition and the degenerative process are good examples. The recognition of so-called atypical forms of AD with early onset has boosted the understanding of subtypes of AD, which will become more important when drugs targeted at the amyloid process become available. Aside from AD, interest in young dementia in general has fuelled research into frontotemporal lobar degeneration (FTLD) and dementias with parkinsonism such as Progressive Supranuclear Palsy (PSP). All data are stored in a clinical database containing information from over 5000 patients. Bodily fluids (blood, CSF, DNA) are stored in our biobank, which currently contains material from over 3000 patients.

unipglogo2.pngThe Università degli Studi di Perugia, founded in 1308, is a modern, multi-campus educational institution whose primary aim is to provide the highest quality degree programs and advanced scientific research and development. By Italian standards it is considered a medium-sized university and is a public institution and a legal entity, that is, it is entitled to award qualifications with legal validity. There are currently more than 26.000 students enrolled at the Università degli Studi di Perugia and 1.100 teaching staff members supported by more than 1.000 administrators. The University offers a wide variety of degree programs in 16 Departments devoted to the study of: Agriculture; Economics; Education; Engineering; Arts and Humanities; Law; Mathematics, Physical and Natural Sciences; Medicine; Pharmacy; Political Science; Veterinary Medicine.

The section of Gerontology and Geriatrics of the Department of Medicine is an Academic Centre where research, teaching and clinical activity are performed. Basic research focuses on the role of oxidative stress, inflammation or metabolic alterations in ageing and age-related diseases and conditions, particularly cognitive impairment dementia, stroke, osteoporosis, sarcopenia and frailty. Clinical research considers the treatment of persons affected by different age-related chronic conditions such as cognitive impairment and dementias, depression, gait problems, falls, osteoporosis and fractures. The centre is focused in detecting and managing all conditions leading to multimorbidity and polytherapy, well recognized risk factors for frailty. The Section comprises a skilled and trained multidisciplinary team (geriatricians, statistician, psychologists) which has already been partner of several national and international research projects and phase 2and phase 3 RCTs and it has a well established international collaboration network. The Section includes a research laboratory of biochemistry and molecular biology for studies on markers in biological specimens (serum, plasma, urine, peripheral cells, CSF) with a particular skill in chromatographic and immunological techniques. In addition, epidemiological studies are performed based on several national and international databases aimed to disentangle the complex relationship between multimorbidity, and disability at older age, and to show the quality of care in different settings, from home to nursing home. In particular the Section leads the the ReGAl project (Geriatric Network on Alzheimer’s disease) that first developed in Italy a EHR for collecting clinical data on a large number of old subjects with cognitive and somatic problems. Teaching of medical students, residents, nurses, and speech therapists takes place. Clinical activities of the Section includes responsibility for an Acute Care Ward (800 pts/year); an Outpatient Clinic (2500 pts/year); a Memory Clinic (800 pts/year), connected with 3T MRI facility and PET facility.

logo_alzheimer.gifAlzheimer Europe was founded in 1989 and currently has 36 member organisations in 32 countries. The organisation considers its mission to change perceptions, practice and policy in order to improve the access by people with dementia and their carers to treatment options and care services.

The strategic plan of Alzheimer Europe defines the priorities of the organisation as:

  • Marking dementia a European priority
  • Supporting policy with facts,
  • Basing our actions on ethical principles and
  • Building a stronger organisation.

Combinostics was founded in August 2014 with the goal to develop and market advanced tools for data-driven diagnostics. The founders have unique know-how in clinical decision support with strong expertise on biomarker discovery. The technology builds on software and innovations that have been developed over many years at VTT Technical Research Centre of Finland.